The BMS CVRs were issued pursuant to a Contingent Value Rights Agreement, dated November 20, 2019 (the “CVR Agreement”). A BMS CVR entitled you to receive a one-time potential payment of $9.00 in cash upon FDA’s approval in specified indications of all three of the following milestones (“CVR milestones”) by the specified timeline:
ozanimod by December 31, 2020,
liso-cel (JCAR017) by December 31, 2020, and
ide-cel (bb2121) by March 31, 2021.